IP Library Granted Patent US 7,754,692
Granted Patent B2
US 7,754,692 · App. 11/593,699 · Granted Jul 13, 2010

Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,692
App. No.
11/593,699
Granted
Jul 13, 2010
Kind
B2
Abstract

The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Claims (9)

1. A method for treating a condition selected from the group consisting of retinopathy of prematurity, diabetic retinopathy, vascular proliferative retinopathy and pathological vascular proliferation wherein the method comprises administering, to a patient who has at least one of these conditions, and is thus in need of such treatment, an amount of the dipeptide arginyl-glutamine, or a salt thereof, that is sufficient to treat the condition.

2. The method, according to claim 1 , wherein the vascular proliferation is associated with tumor growth.

3. The method, according to claim 1 , wherein the vascular proliferation being inhibited is in a mammal.

4. The method, according to claim 3 , which comprises local administration of the dipeptide, or a salt thereof.

5. The method, according to claim 3 , which comprises systemic administration of the dipeptide, or a salt thereof.

6. The method, according to claim 5 , wherein the administration is enteral.

7. The method, according to claim 3 , which comprises oral consumption by the mammal of the dipeptide, or a salt thereof.

8. The method, according to claim 1 , wherein said dipeptide, or salt thereof, is administered in an aqueous formulation.

9. A method for the treatment of a condition that is selected from retinopathy of prematurity, diabetic retinopathy, vascular proliferative retinopathy, and proliferation of abnormal vascularization, in a human patient who has one of these conditions and is thus in need of such treatment, the method comprising enterally administering to the patient a composition comprising arginyl-glutamine dipeptide, or a salt thereof, in an amount that is sufficient to treat the condition.